Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daisuke Yabe

Showing results (51-60 of 253) with videos related to

Pageof 26
Sort By:
JCEM Case Reports|July 26, 2024
Sporadic Parathyroid Carcinoma Treated With Lenvatinib, Exhibiting a Novel Somatic <i>MEN1</i> MutationYu Ito, Toshinori Imaizumi, Hisashi Daido, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 24, 2007
Msx2-interacting nuclear target protein (Mint) deficiency reveals negative regulation of early thymocyte differentiation by Notch/RBP-J signalingMasayuki Tsuji, Reiko Shinkura, Kazuki Kuroda, et al.
Journal of Diabetes and Its Complications|September 7, 2015
Long-term safety of once-daily lixisenatide in Japanese patients with type 2 diabetes mellitus: GetGoal-Mono-JapanYutaka Seino, Daisuke Yabe, Akane Takami, et al.
Expert Opinion on Drug Safety|April 9, 2015
Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse eventsDaisuke Yabe, Rie Nishikino, Makiko Kaneko, et al.
Journal of Diabetes Investigation|May 4, 2021
iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post-hoc analysis of the LixiLan JP-L trialDaisuke Yabe, Katsumi Iizuka, Mike Baxter, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 30, 2024
Quality of Life in Japanese People with Type 2 Diabetes Switching from Multiple Daily Insulin Injections to Once-Daily iGlarLixi: SIMPLIFY JapanHitoshi Ishii, Hideki Kamiya, Yoko Takahashi, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 17, 2002
Three mutations in sterol-sensing domain of SCAP block interaction with insig and render SREBP cleavage insensitive to sterolsDaisuke Yabe, Zong-Ping Xia, Christopher M Adams, et al.
Diabetes, Obesity & Metabolism|January 21, 2026
GLP-1 receptor agonists and cardiovascular outcomes in Asian, Black or African American, and White populations: An updated meta-analysis including the SOUL trialMasashi Hasebe, Chen-Yang Su, Hisashi Kamido, et al.
Expert Opinion on Drug Safety|April 14, 2022
Long-term safety and effectiveness of linagliptin by baseline body mass index in Japanese patients with type 2 diabetes: a 3-year post-marketing surveillance studyDaisuke Yabe, Fumiko Yamamoto, Søren S Lund, et al.
Journal of Diabetes Investigation|October 7, 2017
Beta-cell replacement strategies for diabetesTimothy J Kieffer, Knut Woltjen, Kenji Osafune, et al.
Pageof 26

Showing results (51-60 of 253) with videos related to

Sort By:
Pageof 26
JCEM Case Reports|July 26, 2024
Sporadic Parathyroid Carcinoma Treated With Lenvatinib, Exhibiting a Novel Somatic <i>MEN1</i> MutationYu Ito, Toshinori Imaizumi, Hisashi Daido, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 24, 2007
Msx2-interacting nuclear target protein (Mint) deficiency reveals negative regulation of early thymocyte differentiation by Notch/RBP-J signalingMasayuki Tsuji, Reiko Shinkura, Kazuki Kuroda, et al.
Journal of Diabetes and Its Complications|September 7, 2015
Long-term safety of once-daily lixisenatide in Japanese patients with type 2 diabetes mellitus: GetGoal-Mono-JapanYutaka Seino, Daisuke Yabe, Akane Takami, et al.
Expert Opinion on Drug Safety|April 9, 2015
Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse eventsDaisuke Yabe, Rie Nishikino, Makiko Kaneko, et al.
Journal of Diabetes Investigation|May 4, 2021
iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post-hoc analysis of the LixiLan JP-L trialDaisuke Yabe, Katsumi Iizuka, Mike Baxter, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 30, 2024
Quality of Life in Japanese People with Type 2 Diabetes Switching from Multiple Daily Insulin Injections to Once-Daily iGlarLixi: SIMPLIFY JapanHitoshi Ishii, Hideki Kamiya, Yoko Takahashi, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 17, 2002
Three mutations in sterol-sensing domain of SCAP block interaction with insig and render SREBP cleavage insensitive to sterolsDaisuke Yabe, Zong-Ping Xia, Christopher M Adams, et al.
Diabetes, Obesity & Metabolism|January 21, 2026
GLP-1 receptor agonists and cardiovascular outcomes in Asian, Black or African American, and White populations: An updated meta-analysis including the SOUL trialMasashi Hasebe, Chen-Yang Su, Hisashi Kamido, et al.
Expert Opinion on Drug Safety|April 14, 2022
Long-term safety and effectiveness of linagliptin by baseline body mass index in Japanese patients with type 2 diabetes: a 3-year post-marketing surveillance studyDaisuke Yabe, Fumiko Yamamoto, Søren S Lund, et al.
Journal of Diabetes Investigation|October 7, 2017
Beta-cell replacement strategies for diabetesTimothy J Kieffer, Knut Woltjen, Kenji Osafune, et al.
Pageof 26